Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

447
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
447
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

680
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
680
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.1K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Double-half-H2: A two-electron model system for benchmarking quantum chemical methods across multiple bond types and molecular conformations.

The Journal of chemical physics·2025
Same author

Exploring a New Regime of Molecular Orbital Physics in 4d Cluster Magnets with Resonant Inelastic X-Ray Scattering.

Physical review letters·2025
Same author

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Letter to the editor: My experiences and reversing the attitudinal shift.

Radiography (London, England : 1995)·2023

相关实验视频

Updated: Jan 9, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.5K

在CF亚群中肺部恶化风险的差异

D R VanDevanter1, C O'Rourke2, M W Konstan3

  • 1Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
|November 30, 2025
PubMed
概括
此摘要是机器生成的。

在患有囊性纤维化 (pwCF) 患者中,以前的肺恶化 (PEx) 强烈预测了未来的PEx风险,无论调节剂治疗如何. 即使使用elexacaftor/tezacaftor/ivacaftor (ETI),更高的先前PEx也表明未来风险更大.

关键词:
临床试验的设计前一年的事件频率.肺部恶化风险增加的风险

更多相关视频

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

995
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.8K

相关实验视频

Last Updated: Jan 9, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.5K
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

995
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.8K

科学领域:

  • 肺部医学 肺部医学
  • 药理学 药理学是指药理学的学科.
  • 流行病学 流行病学

背景情况:

  • 肺部恶化 (PEx) 是囊性纤维化 (CF) 管理中的一个关键问题.
  • 评估未来的PEx风险对于治疗策略至关重要.
  • 较新的CFTR调节器疗法,如elexacaftor/tezacaftor/ivacaftor (ETI),对PEx风险的影响需要进一步调查.

研究的目的:

  • 评估前一年PEx频率与CF患者 (pwCF) 未来PEx风险之间的关联.
  • 为了确定这种关联是否在接受ETI的pwCF中持续存在.
  • 为新的CF疗法进行临床试验的设计提供信息.

主要方法:

  • 来自CF基金会患者登记处 (CFFPR) 对12岁以上 (2022-2023) 的pwCF数据的分析.
  • 2022年PEx频率的分层 (零,一,二,三+).
  • 基于2022年PEx频率,疾病阶段,人口统计,感染状况和调节器使用 (没有与ETI) 的2023年PEx危险的建模.

主要成果:

  • 更高的2022年PEx频率与增加的2023年PEx平均值和较短的2023年PEx的时间密切相关.
  • 与没有PEx的PwCF相比,在2022年具有3+PEx的PwCF在2023年具有7.11倍的PEx危险.
  • 普华永道在2022年有一两次PEx的PwCF在2023年有2.89倍的PEx风险.

结论:

  • 前一年的PEx频率是pwCF中未来PEx风险的重要独立预测因素.
  • ETI 降低了 PEx 率,但具有较高 PEx 史的人仍然面临高风险.
  • 未来的治疗干预可以研究在ETI治疗的pwCF中,有频繁PEx的病史.